Codexis [CDXS] vs Vertex [VRTX] Detailed Stock Comparison

Codexis Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Codexis Inc. wins in 5 metrics, Vertex Pharmaceuticals Inc. wins in 14 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Codexis Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 4.52 5.92 Codexis Inc.
Debt-to-Equity Ratio 144.88 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -11.45 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -6.77 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) -62.47% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 35.89% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) 35.89% 39.60% Vertex Pharmaceuticals Inc.
Return on Equity -74.88% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -16.14% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-23.85M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 20.43% 1.24% Codexis Inc.
Price-to-Sales Ratio (TTM) 3.25 9.22 Codexis Inc.
Enterprise Value $223.99M $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 3.18 8.83 Codexis Inc.
Gross Profit Margin (TTM) 94.75% 85.39% Codexis Inc.
Revenue per Share (TTM) $1 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.50 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 2.08 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 7.76% 1.78% Vertex Pharmaceuticals Inc.

Codexis Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

CDXS
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Codexis Inc.0.74%3.46%7.17%163.73%63.03%67.08%
Vertex Pharmaceuticals Inc.0.76%-2.49%-1.11%-12.54%-1.86%-5.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Codexis Inc.20.43%5.32%-86.34%-29.87%-73.94%-80.27%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Codexis Inc. vs Vertex Pharmaceuticals Inc.

MetricCDXSVRTX
Market Information
Market Cap i$228.99M$109.45B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i1,228,7541,057,061
90 Day Avg. Volume i3,001,3681,272,097
Last Close$2.71$428.34
52 Week Range$0.96 - $3.87$362.50 - $507.92
% from 52W High-29.97%-15.67%
All-Time High$42.01 (Nov 08, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-93.55%-17.61%
Growth Metrics
Quarterly Revenue Growth0.81%0.10%
Quarterly Earnings Growth0.81%0.31%
Financial Health
Profit Margin (TTM) i-0.62%0.33%
Operating Margin (TTM) i0.36%0.40%
Return on Equity (TTM) i-0.75%0.23%
Debt to Equity (MRQ) i144.8810.91
Cash & Liquidity
Book Value per Share (MRQ)$0.56$73.49
Cash per Share (MRQ)$0.86$26.01
Operating Cash Flow (TTM) i$-19,376,000$3.63B
Levered Free Cash Flow (TTM) i$-5,074,125$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Codexis Inc. vs Vertex Pharmaceuticals Inc.

MetricCDXS (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-11.4519.95
PEG Ratio i-11.450.88
Price to Sales (TTM) i3.259.22
Price to Book (MRQ) i4.525.92
Market Capitalization
Market Capitalization i$228.99M$109.45B
Enterprise Value i$223.99M$105.96B
Enterprise Value Metrics
Enterprise to Revenue i3.188.83
Enterprise to EBITDA i-6.7721.78
Risk & Other Metrics
Beta i2.080.37
Book Value per Share (MRQ) i$0.56$73.49

Financial Statements Comparison: Codexis Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCDXS (2025)VRTX (2025)
Revenue/Sales i70.39M12.00B
Cost of Goods Sold i9.34M1.65B
COGS % of Revenue i13.3%13.8%
Gross Profit i61.05M10.35B
Gross Margin i86.7%86.2%
Research & Development i52.31M4.04B
Operating Income (EBIT) i-38.33M4.55B
Operating Margin i-54.5%37.9%
EBITDA i-30.46M5.25B
EBITDA Margin i-43.3%43.7%
Pre-Tax Income i-43.93M4.64B
Pre-Tax Income % of Revenue i-62.4%38.7%
Income Tax i47,000690.00M
Income Tax % of Revenue i0.1%5.7%
Net Income (Profit) i-43.97M3.95B
Profit Margin i-62.5%32.9%

Balance Sheet & Liquidity Metrics

MetricCDXS (2025)VRTX (2025)
Cash & Equivalents i50.79M5.08B
Total Current Assets i96.82M11.20B
Total Current Assets % of Revenue i137.5%93.3%
Total Current Liabilities i25.32M3.86B
Total Current Liabilities % of Revenue i36.0%32.2%
Long-Term Debt i70.26M1.95B
Long-Term Debt % of Revenue i99.8%16.3%
Total Shareholders Equity i50.53M18.67B
Retained Earnings i-606.78M13.56B
Retained Earnings % of Revenue i-862.1%113.0%
Property, Plant & Equipment i69.44M1.56B

Cash Flow Statement Comparison

MetricCDXS (2025)VRTX (2025)
Operating Cash Flow i-19.68M3.77B
Operating Cash Flow % of Revenue i-28.0%31.4%
Capital Expenditures i-4.47M-437.60M
Free Cash Flow i-23.85M3.19B
FCF Margin i-33.9%26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricCDXSVRTX
Shares Short i6.94M4.02M
Short Ratio i1.662.80
Short % of Float i7.76%1.78%
Shares Outstanding i90.48M253.99M
Float Shares i72.95M253.24M
% Held by Insiders i7.57%0.21%
% Held by Institutions i74.75%97.60%
% Held by Public i17.68%2.19%

Dividend Analysis & Yield Comparison: Codexis Inc. vs Vertex Pharmaceuticals Inc.

MetricCDXSVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A